Pharmaceutical Industry Information Portal

Pfizer and BioNTech announce new $3.2 billion agreement to supply the COVID-19 vaccine to the US

Pfizer Inc. and BioNTech SE announced today a new vaccine supply agreement with the U.S. government, according to which the U.S. government will receive 105 million doses for $3.2 billion, with an option to purchase up to 195 million additional doses.

The agreement provides additional doses for U.S. residents and helps cope with the next COVID-19 wave, with the doses expected to be delivered as soon as late summer 2022 and continue into Q4.

Albert Bourla, Chairman and Chief Executive Officer, Pfizer, said:

As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that may provide protection against current and future variantsю Vaccines have been and will remain critical to protecting people of all ages against COVID-19. We remain proud of our long-term partnership with the U.S. government in helping to address this pandemic, and of the ongoing impact of vaccination efforts in the U.S. and around the world.


Expert Articles